064550.KQ
Bioneer Corporation
KOE · Healthcare · Biotechnology · KR
KRW 10,240.00
+2.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 345.9B | 330.1B | 294.0B | 263.2B | 218.4B |
| Cost of Revenue | 81.1B | 76.3B | 74.1B | 60.2B | 55.0B |
| Gross Profit | 264.8B | 253.8B | 219.9B | 203.0B | 163.4B |
| Operating Expenses | |||||
| R&D Expense | 17.4B | 18.9B | 19.2B | 15.0B | 16.8B |
| SG&A Expense | 214.6B | 196.5B | 177.6B | 151.5B | 134.2B |
| General & Admin Expense | 3.6B | 4.4B | 5.2B | 5.6B | 4.1B |
| Selling & Marketing Expense | 144.8B | 192.1B | 172.4B | 145.8B | 100.2B |
| Other Expenses | 34.2B | 30.5B | 36.6B | 35.7B | 1.7B |
| Total Operating Expenses | 263.4B | 245.9B | 233.3B | 202.2B | 152.7B |
| Cost and Expenses | 340.8B | 322.2B | 307.4B | 262.4B | 207.7B |
| Operating Income (EBIT) | 765.6M | 7.9B | (13.4B) | 791.8M | 11.5B |
| Non-Operating | |||||
| Interest Income | 2.0B | 1.9B | 1.6B | 1.3B | 539.3M |
| Interest Expense | 4.6B | 4.6B | 3.4B | 1.4B | 647.9M |
| Net Interest Income | (2.6B) | (2.8B) | (1.8B) | (103.2M) | (108.6M) |
| Other Non-Op Income/Expense | (1.9B) | 2.0B | (1.9B) | (858.8M) | 2.3B |
| Non-Operating Income (excl Interest) | (1.2B) | — | (1.5B) | (548.9M) | (3.0B) |
| EBT (Pre-Tax Income) | 3.3B | 9.9B | (15.3B) | (67.0M) | 13.9B |
| Income Tax Expense | 7.0B | 8.2B | 3.7B | 6.9B | (1.2B) |
| Bottom Line | |||||
| Net Income | (6.7B) | (2.8B) | (20.6B) | (10.6B) | 12.1B |
| Earnings from Cont. Ops | (3.7B) | 1.7B | (19.0B) | (6.9B) | 15.1B |
| Earnings from Discont. Ops | — | — | — | 472.5M | — |
| Bottom Line Net Income | (6.7B) | (2.8B) | (20.6B) | (10.6B) | 12.1B |
| Per Share | |||||
| Basic EPS | (₩776) | (₩109) | (₩798) | (₩410) | ₩468 |
| Diluted EPS | (₩259) | (₩109) | (₩798) | (₩410) | ₩468 |
| Revenue Per Share | ₩13,403 | ₩12,790 | ₩11,390 | ₩10,199 | ₩8,462 |
| Shares | |||||
| Basic Shares Outstanding | 25.8M | 25.8M | 25.8M | 25.8M | 25.8M |
| Diluted Shares Outstanding | 25.8M | 25.8M | 25.8M | 25.8M | 25.8M |
| Profitability Metrics | |||||
| EBITDA | (59.2B) | 16.9B | (2.8B) | 10.3B | 21.8B |
| D&A | 8.5B | 9.0B | 9.1B | 9.0B | 7.3B |
| EBIT | (67.7B) | 7.9B | (11.9B) | 1.3B | 14.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026